OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
First advanced hybrid closed-loop insulin pump system in India features automatic insulin delivery, automatic correction boluses, and bluetooth connectivity
Laxxon Medical has developed a 3D screen printing technology for the manufacture of structured tablets that enables the controlled release of active pharmaceutical ingredients over time
Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category
A simple blood test detects over 30 types of cancers
Dr. Muffazal Lakdawala performs the largest series of complete robotic gastric bypass surgery in India
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Subscribe To Our Newsletter & Stay Updated
